Association between methylenetetrahydrofolate reductase genetic polymorphisms and efficacy and safety of methotrexate in the treatment of rheumatoid arthritis:a Meta-analysis
10.13699/j.cnki.1001-6821.2017.14.018
- VernacularTitle:亚甲基四氢叶酸还原酶基因多态性与甲氨蝶呤治疗类风湿关节炎疗效和安全性的Meta分析
- Author:
Xiao-Lei REN
1
;
Yi-Qiu ZHAN
;
Chun-Yan ZHANG
;
Wan-Yu FENG
Author Information
1. 北京大学人民医院药剂科,北京100044
- Keywords:
methylenetetrahydrofolate reductase;
genetic polymorphism;
methotrexate;
rheumatoid arthritis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(14):1351-1353
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and efficacy and adverse drug reactions of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in Chinese population.Methods Retrieved from CNKI,VIP,Wanfang,China biology medicine(CBM),PubMed,EmBase and Cochrane Library,case control studies about the relationship between MTHFRC677T and A1298C genetic polymorphisms and efficacy and adverse drug reactions of MTX in the treatment of rheumatoid arthritis were collected.Meta-analysis was performed by software of RevMan 5.3.Results Five studies involving 449 participants were included,and five involved MTHFR C677T,three involved A1298C.The Meta-analysis showed that compared with 1298AC/CC,1298AA had a lower clinical efficacy (P ＜0.05);and compared with 677CT/TT,677CC had a lower risk of adverse drug reactions (P ＜ 0.05).Conclusion MTHFR C677T and A1298C polymorphisms seem to be influence the efficacy and adverse drug reactions of methotrexate in the treatment of rheumatoid arthritis in Chinese population.However,the evidence was not strong due to the quantity of the studies.Further study for association of MTHFR polymorphisms with MTX efficacy and toxicities should be needed in larger RA population.
